ELISA: Protocols
Overview
The enzyme-linked immunosorbent assay (ELISA) is a frequently used application which determines the concentration of an analyte in solution. The ELISA method is straightforward and rapid. With automated equipment the assay is easily scalable for set up in high-throughput and can handle a large number of samples in parallel, making it a popular choice for the evaluation of research and diagnostic targets.
General ELISA Protocols
Standard methods for different types of ELISA in 96-well microtiter plate format, including recommended buffers.
- Indirect
- Competition (Inhibition)
- Direct ELISA with streptavidin-biotin detection
- Sandwich ELISA with streptavidin-biotin detection
- Sandwich ELISA with direct detection
Protocols For Use With Anti-Biotherapeutic Antibodies
Bio-Rad’s anti-biotherapeutic antibodies are ideal for the measurement of monoclonal antibody drugs and biosimilar products in PK and ADA assays.
We have developed a range of highly specific, recombinant anti-idiotypic antibodies with different binding modes and properties, enabling the development of bridging ELISA and antigen capture ELISA. Protocols are available for each type of PK assay and ADA assay for many of the anti-biotherapeutic products in our catalog.
Anti-idiotypic AntibodiesPK and ADA Bridging ELISA Protocols
Bridging ELISA is a special case of a sandwich ELISA in which a dimeric or oligomeric antigen (most often an antibody in a sample) is detected by a capture and detection antibody. The antigen bridges the two specific antibodies. Bridging ELISAs are most frequently used for the detection of IgG, for example in pharmacokinetic (PK) or anti-drug antibody (ADA) assays.
PK Bridging ELISA measuring free drug
Type 1 anti-idiotypic antibodies are inhibitory and are used to detect free drug
- Abatacept
- Adalimumab
- Aflibercept
- Aflibercept
- Atezolizumab
- Avelumab
- Avelumab
- Belatacept
- Belimumab
- Benralizumab
- Bevacizumab
- Brentuximab vedotin
- Burosumab
- Canakinumab
- Cemiplimab
- Cetuximab
- Daratumumab
- Denosumab
- Dulaglutide
- Dupilumab
- Durvalumab
- Eculizumab
- Elotuzumab
- Emicizumab
- Etanercept
- Evolocumab
- Golimumab
- Guselkumab
- Infliximab
- Ixekizumab
- Ipilimumab
- Natalizumab
- Nivolumab
- Obinutuzumab
- Ocrelizumab
- Ocrelizumab
- Omalizumab
- Palivizumab
- Panitumumab
- Pembrolizumab
- Pertuzumab
- Pertuzumab
- Ramucirumab
- Ramucirumab
- Risankizumab
- Rituximab
- Romosozumab
- Sarilumab
- Sarilumab
- Secukinumab
- Tocilizumab
- Trastuzumab
- Trastuzumab
- Trastuzumab
- Trastuzumab
- Ustekinumab
- Ustekinumab
- Vedolizumab
PK Bridging ELISA measuring total drug
Type 2 anti-idiotypic antibodies are non-inhibitory and enable the measurement of total drug – free, partially and fully bound
PK Bridging ELISA measuring Antibody Drug Conjugates
ADA Bridging ELISA
Type 1 anti-idiotypic antibodies are neutralizing and fully human; in immunoglobulin format they can be used as a control or calibrator as a surrogate for human ADAs
- Abatacept
- Adalimumab (IgG1)
- Adalimumab (IgE)
- Aflibercept
- Atezolizumab
- Avelumab
- Belatacept
- Belimumab
- Benralizumab
- Bevacizumab
- Brentuximab vedotin
- Canakinumab
- Cemiplimab
- Certolizumab pegol
- Cetuximab
- Daratumumab
- Denosumab
- Dupilumab
- Durvalumab
- Eculizumab
- Elotuzumab
- Emicizumab
- Etanercept
- Evolocumab
- Guselkumab
- Ixekizumab
- Infliximab
- Ipilimumab
- Natalizumab
- Nivolumab
- Obinutuzumab
- Ocrelizumab
- Omalizumab
- Palivizumab
- Panitumumab
- Pembrolizumab
- Pertuzumab
- Ramucirumab
- Ranibizumab
- Risankizumab
- Rituximab
- Romosozumab
- Sarilumab
- Secukinumab
- Tocilizumab
- Trastuzumab
- Ustekinumab
- Vedolizumab
Antigen Capture ELISA Protocols
A third type of antibody that only detects drug bound to its target antigen is available for some of our specificities.
PK Antigen Capture ELISA measuring bound drug exclusively
A Type 3 antibody is used in an antigen capture ELISA to detect bound drug exclusively and avoids the bridging ELISA format
- Adalimumab
- Atezolizumab
- Atezolizumab
- Avelumab
- Avelumab
- Benralizumab
- Benralizumab
- Burosumab
- Burosumab
- Golimumab
- Durvalumab
- Ipilimumab
- Ipilimumab
- Omalizumab
- Pertuzumab
- Ramucirumab
- Ranibizumab
- Ranibizumab
- Romosozumab
- Romosozumab
- Secukinumab
- Trastuzumab
Resources
Technical Support
Be the First to Receive Updates on Products and Resources
Regular communications will include:
- Free resources for your lab including application guides, posters, mini-reviews, protocols, and practical tips
- Notifications about new online tools to support your research, like our spectraviewer tool
- Fab Fragments enewsletter, a monthly snapshot of our latest antibody news
- Flow. Sorted. enewsletter, dedicated to flow cytometry
- RiVETing enewsletter, dedicated news for veterinary researchers
- New product launches, such as our recent launch of TrailBlazer™ Antibodies using unique SpyTag technology
- StarBright™ Dyes – updates on our expanding range of unique proprietary, fluorescent nanoparticles, especially designed for flow cytometry
- Webinar invitations
- Special offers and more
Through the sign-up process, you will have the option to select your areas of interest to make sure you only receive information relevant to you.
You will be able to unsubscribe easily at any time.
